Next report date
Report period
H1 2024
EPS estimate
−1.17HKD
Revenue estimate
923.52 MHKD
−2.9HKD
−577.04 MHKD
1.70 BHKD
12.05 M
About SICHUAN KELUN-BIOTECH BIOPHARMACEUT
Sector
CEO
Jun You Ge
Headquarters
Chengdu
Employees (FY)
1.42 K
Founded
2016
ISIN
CNE1000062J1
FIGI
BBG01H7W3K69
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. engages in the research and development, manufacture, and commercialization of novel drugs. It offers proprietary technology platforms focusing on the treatment of breast cancer, non-small cell lung cancer, gastrointestinal cancers, and colorectal cancer, as well as non-oncology diseases. The company was founded by Ge Xin Liu on November 22, 2016 and is headquartered in Chengdu, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 6990 is 164.0 HKD — it has decreased by 2.26% in the past 24 hours. Watch SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SICHUAN KELUN-BIOTECH BIOPHARMACEUT stocks are traded under the ticker 6990.
SICHUAN KELUN-BIOTECH BIOPHARMACEUT is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
6990 stock is 7.13% volatile and has beta coefficient of 1.21. Track SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock price on the chart and check out the list of the most volatile stocks — is SICHUAN KELUN-BIOTECH BIOPHARMACEUT there?
6990 earnings for the last quarter are −0.18 HKD per share, whereas the estimation was −3.93 HKD resulting in a 95.33% surprise. The estimated earnings for the next quarter are −1.50 HKD per share. See more details about SICHUAN KELUN-BIOTECH BIOPHARMACEUT earnings.
SICHUAN KELUN-BIOTECH BIOPHARMACEUT revenue for the last quarter amounts to 1.13 B HKD despite the estimated figure of 430.14 M HKD. In the next quarter revenue is expected to reach 904.76 M HKD.
Yes, you can track SICHUAN KELUN-BIOTECH BIOPHARMACEUT financials in yearly and quarterly reports right on TradingView.
6990 stock has risen by 6.56% compared to the previous week, the month change is a 5.74% rise, over the last year SICHUAN KELUN-BIOTECH BIOPHARMACEUT has showed a 170.63% increase.
6990 net income for the last quarter is −586.63 M HKD, while the quarter before that showed −35.21 M HKD of net income which accounts for −1.57 K% change. Track more SICHUAN KELUN-BIOTECH BIOPHARMACEUT financial stats to get the full picture.
No, 6990 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 6990 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock right from TradingView charts — choose your broker and connect to your account.
6990 reached its all-time high on Mar 25, 2024 with the price of 177.9 HKD, and its all-time low was 60.6 HKD and was reached on Jul 11, 2023. View more price dynamics on 6990 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 4, 2024, the company has 1.42 K employees. See our rating of the largest employees — is SICHUAN KELUN-BIOTECH BIOPHARMACEUT on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SICHUAN KELUN-BIOTECH BIOPHARMACEUT technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock shows the buy signal. See more of SICHUAN KELUN-BIOTECH BIOPHARMACEUT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SICHUAN KELUN-BIOTECH BIOPHARMACEUT future price: according to them, 6990 price has a max estimate of 209.33 HKD and a min estimate of 131.48 HKD. Watch 6990 chart and read a more detailed SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock forecast: see what analysts think of SICHUAN KELUN-BIOTECH BIOPHARMACEUT and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SICHUAN KELUN-BIOTECH BIOPHARMACEUT EBITDA is −409.51 M HKD, and current EBITDA margin is −26.18%. See more stats in SICHUAN KELUN-BIOTECH BIOPHARMACEUT financial statements.